Zacks Investment Research | Nov 13, 2019 03:39AM ET
Syneos Health (NASDAQ:SYNH) recently collaborated with AI and advanced data analytics company AiCure to drive faster and smarter trials to optimize patient engagement. The partnership augments a pre-existing relationship, thus responding to rising demand for digital solutions that change behavior and improve patients’ lives.
Per the terms of the agreement, Syneos Health’s behavioral insights-driven product development model will be integrated with AiCure’s patented intelligent software and AI-driven insights. This will make the capturing, analyzing and predicting of patient behavior that influences clinical trial adherence easier.
With the AiCure collaboration, Syneos Health aims to strengthen hold in the global patient engagement solutions market.
More on the Partnership
The collaboration demonstrates Syneos Health’s commitment to implement innovative technologies in clinical research. The agreement provides the company with a clinically-corroborated, scalable and patient-centric technology platform which can analyze how people respond to treatment.
The platform identifies adherence patterns and variation in site and participant engagement, with the provision of modifying behaviors that increase compliance. This will, in turn, help improve the chances of trial success.
Unlike in the traditional self-reporting measures, patients will be able to access a smartphone application to automatically guide and confirm proper administration in real-time. AiCure’s computer vision algorithms verify whether the correct participant is taking the right medication and confirms ingestion.
Rationale Behind the Partnership
Per Syneos Health’s management, the collaboration will align the company’s product development model and also harness behavioral insights to provide real world understandings. The company believes that the collaboration will reinforce its Dynamic Assembly philosophy, collaborating with the data and technology partner to cater to customers’ needs.
Further, Syneos Health will be granted access to AiCure’s digital biomarker assessments. The patient data will be secured and protected by AiCure’s technology and also perform its assigned function of evaluating movement variables to objectively study known clinical endpoints.
Syneos Health, a key player in the global Contract Research Organization and Contract Commercial Organization, will be able to expand its outreach to various biopharmaceutical companies along with enabling customer engagement.
Industry Prospects
Per a report by Zacks Investment Research
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.